ESSA Pharma to Present at the Jefferies Global Healthcare Conference

5/30/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EPIX alert in real time by email

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York.

David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

Contacts

ESSA Pharma, Inc.

Peter Virsik, Chief Operating Officer

778.331.0962

[email protected]

Investors and Media:

Argot Partners

212.600.1902

essa@argotpartners.com

View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-the-jefferies-global-healthcare-conference-302158625.html

SOURCE ESSA Pharma Inc

Get the next $EPIX alert in real time by email

Date	Price Target	Rating	Analyst
6/26/2023	$17.00	Outperform	Oppenheimer
8/17/2021	$36.00 → $22.00	Outperform	Oppenheimer

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $EPIX

$EPIX Press Releases

Fastest customizable press release news feed in the world

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

$EPIX SEC Filings

ESSA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

ESSA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by ESSA Pharma Inc.

$EPIX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Virsik Peter sold $4,185 worth of shares (694 units at $6.03), decreasing direct ownership by 8% to 7,776 units (SEC Form 4)

Chief Operating Officer Virsik Peter sold $4,164 worth of shares (694 units at $6.00), decreasing direct ownership by 8% to 8,470 units (SEC Form 4)

Chief Operating Officer Virsik Peter sold $12,554 worth of shares (2,082 units at $6.03), decreasing direct ownership by 19% to 9,164 units (SEC Form 4)

$EPIX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

SEC Form SC 13G filed by ESSA Pharma Inc.

SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

$EPIX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer resumed coverage on ESSA Pharma with a new price target

Oppenheimer reiterated coverage on ESSA Pharma with a new price target

Piper Sandler initiated coverage on ESSA Pharma with a new price target

$EPIX Market Insights

Live Market Insights

Oppenheimer Maintains Outperform on ESSA Pharma, Maintains $17 Price Target

ESSA Pharma: Q1 Earnings Insights

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

$EPIX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$EPIX Leadership Updates

Live Leadership Updates

$EPIX Financials

Live finance-specific insights

Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Recent Analyst Ratings for
$EPIX

$EPIX
Press Releases

$EPIX
SEC Filings

$EPIX
Insider Trading

$EPIX
Large Ownership Changes

$EPIX
Analyst Ratings

$EPIX
Market Insights

$EPIX
Insider Purchases

$EPIX
Leadership Updates

$EPIX
Financials